Abstract
The goal of this study was to investigate the serological titers of circulating antibodies against human papillomavirus (HPV) type 16 (anti-HPV16) prior to the detection of an incident HPV16 or HPV31 infection amongst vaccinated participants. Patients were selected from a prospective post-HPV vaccine longitudinal cohort at Mount Sinai Adolescent Health Center in Manhattan, NY. We performed a nested case–control study of 43 cases with incident detection of cervical HPV16 (n = 26) or HPV31 (n = 17) DNA who had completed the full set of immunizations of the quadrivalent HPV vaccine (4vHPV). Two control individuals whom had received three doses of the vaccine (HPV16/31-negative) were selected per case, matched on age at the first dose of vaccination and follow-up time in the study: a random control, and a high-risk control that was in the upper quartile of a sexual risk behavior score. We conducted an enzyme-linked immunosorbent assay (ELISA) for the detection of immunoglobulin G (IgG) antibodies specific to anti-HPV16 virus-like particles (VLPs). The results suggest that the average log antibody titers were higher among high-risk controls than the HPV16/31 incident cases and the randomly selected controls. We show a prospective association between anti-HPV16 VLP titers and the acquisition of an HPV16/31 incident infection post-receiving three doses of 4vHPV vaccine.
Highlights
Cervicovaginal infection by human papillomavirus (HPV) is the most common sexually transmitted infection in young adults
We included a random control group (RC) that was matched on age at first dose of 4vHPV, having completed three doses of HPV vaccine and being HPV-negative for HPV16 and 31
When modeled individually and comparing each type of control to the HPV16/31 incident case, the results suggested that the high-risk controls had a 73% higher likelihood (OR = 1.73, 95% CI: 1.03–2.88; p = 0.04) of having a one-unit increase in log antibody titers
Summary
Cervicovaginal infection by human papillomavirus (HPV) is the most common sexually transmitted infection in young adults. For women participating in the bivalent [10], quadrivalent [11,12,13,14,15], and the nonavalent [16] HPV vaccine trials, effective protection from high-grade cervical intraepithelial neoplasia (CIN) has been demonstrated for up to 10 years among 18–26 years of age, especially among women naïve to the vaccine HPV type at vaccination. Prior reports on the immunogenicity of the HPV vaccine among children with HIV were mostly limited to 7 months post-initial vaccine dose [17,18,19,20,21] These studies demonstrated safety and seroconversion rates above 90% amongst HIV-infected individuals, the anti-HPV type-specific antibody’s titers were lower in the group with higher HIV viral loads [22]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
